Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
India
/
Pharmaceuticals & Biotech
/
Tarsons Products
TARSONS
Tarsons Products
Rising Environmental Costs And Automation Will Erode Lab Markets
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
01 Aug 25
Updated
01 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
₹347.00
0.7% undervalued
intrinsic discount
01 Aug
₹344.50
Loading
1Y
-23.4%
7D
-4.5%
Author's Valuation
₹347.0
0.7% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
₹347.0
0.7% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
6b
2019
2021
2023
2025
2027
2028
Revenue ₹6.0b
Earnings ₹1.2b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
14.06%
Life Sciences revenue growth rate
0.33%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
13.81%
Calculation
₹1.17b
Earnings '28
x
22.75x
PE Ratio '28
=
₹26.52b
Market Cap '28
₹26.52b
Market Cap '28
/
51.94m
No. shares '28
=
₹510.67
Share Price '28
₹510.67
Share Price '28
Discounted to 2025 @ 13.70% p.a.
=
₹347.39
Fair Value '25
